The Pill Penalty and Orphan Drug Expansion Are Reshaping Drug Development Pipelines Right Now
The IRA's most commercially consequential structural feature is not the negotiated prices themselves but the timeline asymmetry known as the pill penalty: small-molecule drugs, which are typically oral medications, become eligible for Medicare price negotiation seven years after FDA approval, while biologic drugs administered by injection or infusion do not become eligible until thirteen years after approval. This six-year differential creates a direct financial incentive for pharmaceutical companies to invest in biologic drug development rather than small molecules, even for disease areas where a small-molecule oral drug would be more convenient, more accessible, and potentially more effective for patients. The 2025 reconciliation law's Working Families Tax Cuts Act modified the pill penalty by directing HHS to work toward aligning the negotiation timelines for small molecules and biologics, but the underlying structural incentive remains in place pending rulemaking. Drug development decisions made in 2025 and 2026 will flow through the pipeline over the next decade, meaning the pipeline composition changes driven by this incentive will become visible in what reaches patients in the early 2030s — a horizon that most 2026 healthcare coverage is not modeling explicitly.
The orphan drug exclusion expansion in the 2025 reconciliation law significantly broadens which drugs can avoid Medicare price negotiation, creating a more complex commercial landscape for rare disease therapeutics. Under the original IRA, drugs with orphan drug designation for a single rare disease were excluded from negotiation only if their sole FDA-approved indication was for that disease. The Working Families Tax Cuts Act broadened this exclusion in ways that pharmaceutical companies are actively mapping through their pipeline portfolios, because a drug that can secure orphan designation for a rare disease indication while pursuing additional indications in more common conditions now has a structurally different negotiation exposure profile than the same drug would have had under the original IRA framework. For device companies, particularly those whose products are used in conjunction with these pharmaceutical therapies, the shift in drug development incentives has downstream implications for which therapy combinations reach market and how quickly, because the device ecosystem around a biologic infusion therapy looks quite different from the device ecosystem around an oral small-molecule.
Wegovy on the 2028 Negotiation List Changes the GLP-1 Market Structure
CMS selecting Wegovy for the 2026 negotiation cycle — with a negotiated price taking effect in January 2028 — is the single most commercially significant drug selection in the program's history so far, for reasons that extend well beyond the obesity market itself. Wegovy's inclusion confirms that the program will reach blockbuster GLP-1 medications with annual Medicare spending in the billions, which changes the revenue projections that have been driving astronomical valuations for GLP-1 manufacturers and the downstream device and services markets built around GLP-1 adoption. The Medicare coverage constraint currently limiting Wegovy coverage to its cardiovascular indication rather than its obesity indication is a separate policy question that affects 2026 and 2027 enrollment, but the 2028 negotiated price will apply regardless of how that coverage constraint resolves — meaning the revenue trajectory that GLP-1 manufacturers built their 2028-to-2033 projections around is now subject to a government-determined price ceiling that was not in the original forecast models.
For the broader US healthcare industry, Wegovy's inclusion signals that the Medicare drug price negotiation program will be applied to the highest-spending drug categories regardless of therapeutic area or payer advocacy, which changes the risk calculation for every future blockbuster drug development program. The companies best positioned for this environment are those that built negotiation strategy into their drug development programs at the Phase 2 stage rather than as a commercialization afterthought — generating the health economic evidence, the comparative effectiveness data, and the population-level outcomes data that the CMS maximum fair price methodology weighs, rather than discovering at the point of price negotiation that their evidence base was built for FDA approval rather than for demonstrating value against a Medicare-administered pricing standard.
Build the Value Narrative Early or Pay for It Later: Wegovy's inclusion in the 2026 negotiation cycle proves no blockbuster is safe from the program. Pharma companies still treating Medicare negotiation as a commercialization-stage problem are making a pipeline strategy error that will cost them at the maximum fair price table — the evidence that moves that needle is built in Phase 2, not in the year before launch.